Oral formulation of AKYNZEO gains approval for use in Korea

Swiss pharmaceutical group, Helsinn, and professional pharmaceutical subsidiary of CJ Group, CJ Healthcare, have announced that the oral formulation of AKYNZEO has been approved for use in Korea by the Korean Ministry of Food and Drug Safety (MFDS).

AKYNZEO — an oral fixed combination product — is approved for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy and prevention of acute and delayed nausea and vomiting associated with moderately emetogenic cancer chemotherapy.

“Helsinn is committed to helping people live with the side effects of cancer in a way which allows them to get the best out of every day. AKYNZEO has demonstrated compelling efficacy in helping patients manage the side-effects of cancer chemotherapy,” commented Riccardo Braglia, Helsinn Group vice chairman and CEO. “We’re delighted that the Korean Ministry of Food & Drug Safety has approved AKYNZEO. We are also delighted to be working with CJ Healthcare, a trusted local partner who we believe will help us work to reach as many people as possible to help them to benefit from this new treatment option.”

“AKYNZEO is able to offer significant benefits to patients in enabling them to manage the side effects of cancer chemotherapy and improve quality of life,” added Seok-Hee Kang, chief executive officer of CJ HealthCare. “We are delighted that it is now approved for use in Korea and look forward to working with Helsinn to bring this to more of the patients who need it, and to consolidate our strong market position in supportive care products in Korea.”

CJ HealthCare licensed AKYNZEO from Helsinn in 2012.